Determinants of antileukemia effects of allogeneic NK cells.
In HLA-nonidentical bone marrow transplantation, we studied the characteristics of donor NK cells, recipient leukemia cells, and the cytokine environment that predict the antileukemia effects of allogeneic NK cells. We found that the risk of relapse in pediatric patients with hematologic malignancies was best predicted by a model taking into consideration the presence of inhibitory killer cell Ig-like receptors (KIRs) on the donor's NK cells and the absence of corresponding KIR ligand in the recipient's HLA repertoire (a receptor-ligand model). The risk of relapse was prognosticated less precisely by the Perugia donor-recipient KIR ligand-ligand mismatch model or by a natural cytotoxicity model. In contrast to the ligand-ligand model, we found that the new receptor-ligand model was accurate when analysis was applied to patients with lymphoid malignancy. These findings corroborate our observations that the recipient's KIR repertoire, which was derived from highly purified, HLA-disparate CD34+ cells, resumed a donor-specific pattern within 3 mo of transplantation, but did not correlate evidently with the donor or recipient ligand repertoire. In an in vitro assay and an in vivo mouse model, human NK cell cytotoxicity toward human leukemia cells with 11q23 chromosomal rearrangement increased with the number of receptor-ligand mismatch pairs or prestimulation with IL-12 and IL-18. These findings provide new insights into the determinants of antileukemia effects of allogeneic NK cells and therapeutic strategies.
Leung
Wing
W
Department of Hematology-Oncology, St. Jude Children's Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105, USA. wing.leung@stjude.org
Iyengar
Rekha
R
Turner
Victoria
V
Lang
Peter
P
Bader
Peter
P
Conn
Paul
P
Niethammer
Dietrich
D
Handgretinger
Rupert
R
D000293:Adolescent; D000818:Animals; D045744:Cell Line, Tumor; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000096:biosynthesis / Q000502:physiology; D003601:Cytotoxicity Tests, Immunologic / Q000379:methods / Q000706:statistics & numerical data; D006680:HLA Antigens / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000706:statistics & numerical data; D006650:Histocompatibility Testing; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000706:statistics & numerical data; D007223:Infant; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000276:immunology* / Q000637:transplantation*; D007938:Leukemia / Q000276:immunology* / Q000628:therapy*; D007942:Leukemia, Experimental / Q000276:immunology / Q000628:therapy; D008024:Ligands; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011971:Receptors, Immunologic / Q000008:administration & dosage / Q000096:biosynthesis / Q000378:metabolism; D054340:Receptors, KIR; D012307:Risk Factors; D012680:Sensitivity and Specificity
D016207:Cytokines; D006680:HLA Antigens; D008024:Ligands; D011971:Receptors, Immunologic; D054340:Receptors, KIR